JAK3 and hepatocellular carcinoma: Currently, few treatment options are available (3, 24), with the Janus kinase (JAK) 1/2 inhibitor baricitinib approved for treatment of severe AA in adults and the JAK3/tyrosine kinase expressed in hepatocellular carcinoma (TEC) inhibitor ritlecitinib recently approved for treatment of severe AA in adolescents and adults (25, 26).